Last updated: May 26, 2026
PROMACTA (eltrombopag) suppliers: active ingredient, finished-dose manufacturers, and key distribution sources
PROMACTA (eltrombopag) is marketed in the US by Novartis Pharmaceuticals Corporation and is manufactured under Novartis’s global manufacturing network using supply chains for the active pharmaceutical ingredient (API) and finished drug product. Public “supplier” visibility in PROMACTA is typically split across (i) API manufacturers for eltrombopag and (ii) drug product manufacturing sites for PROMACTA tablets, with additional entities involved in primary packaging, distribution, and label control.
Because PROMACTA is an established, branded solid oral product with ongoing generic/biosimilar competition risk primarily driven by regulatory entry after patent and exclusivity expiry, supplier data should be treated as two separable layers: the validated drug substance (eltrombopag) supply and the validated drug product/tablet supply for the NDA.
Quick mapping of who supplies what (commercially actionable framing)
- Brand holder / NDA marketing authorization (US): Novartis Pharmaceuticals Corporation.
- Drug product (finished tablets): supplied through Novartis’s commercial manufacturing sites (identified in FDA labeling and manufacturing sections when listed).
- Drug substance (eltrombopag API): supplied through contracted API manufacturers within Novartis’s qualified supply network (identified via FDA manufacturing disclosures and/or DMF-linked listings when available).
- Distribution / logistics: handled by Novartis commercial distribution entities and third-party logistics partners supporting US wholesaler channels (not typically named at the tablet-level in public-facing sources).
If a “supplier list” is needed for vendor qualification, compliance, or mitigation planning, the actionable approach is to anchor to FDA-validated manufacturing sites for the specific NDA strengths and dosage forms, then map API supply via DMF associations.
Who manufactures PROMACTA tablets in the US and what sites are listed in FDA records?
Answer (structure): PROMACTA tablets are produced by one or more Novartis-validated drug product manufacturing sites for the NDA. The definitive list of tablet manufacturing sites is in the product’s FDA labeling/manufacturing section and related FDA records tied to the NDA and supplements.
Dosage forms and strengths covered
- PROMACTA is marketed as tablets containing eltrombopag in multiple strengths (commonly 12.5 mg, 25 mg, 50 mg, 75 mg and dosing-dependent tablets in practice).
- The manufacturing authorization usually covers the tablet dosage forms across these strengths with site-level manufacturing equivalence or site-specific coverage depending on batch-release and packaging.
What to look for in FDA manufacturing listings
For operational supplier mapping, the key fields to extract from FDA product labeling and associated manufacturing records are:
- Manufacturer of drug product (tablet manufacturing site)
- Packaging site(s) (bottling/blister packaging, label control)
- Repackager/secondary manufacturer (if applicable)
- NDA sponsor and labeler fields for distribution footprint
These fields are where a procurement team can convert “supplier” into audit-ready candidates.
Who supplies eltrombopag (PROMACTA API) and how is API sourcing typically structured?
Answer (structure): Eltrombopag API supply is sourced from one or more qualified API manufacturers linked to Novartis’s drug substance supply chain. API sourcing is typically controlled through:
- DMF-linked qualification (drug master file associations)
- Quality agreements and validated process controls
- Batch release coordination with drug product sites
How API suppliers show up in public sources
API supplier visibility commonly appears via:
- FDA manufacturing disclosure tied to the NDA, sometimes including API site(s)
- DMF-linked references when publicly indexed
- Import/Customs and trade documentation, usually not sufficient for regulatory-grade supplier validation
API risk lens for supplier decisions
Procurement and litigation teams typically assess:
- Second-source availability for eltrombopag API
- DMF status and API process transferability
- Time to qualify (regulatory and validation burden)
- Single-site manufacturing exposure (if only one drug substance site is listed)
What is PROMACTA’s labeling “manufacturer” information and how do labeler vs manufacturer roles differ?
Answer (structure): US PROMACTA labeling generally distinguishes:
- Applicant/marketing authorization holder (Novartis Pharmaceuticals Corporation)
- Manufacturer of drug substance (API) where disclosed
- Manufacturer of drug product (tablet manufacturing)
- Distributor/labeler functions for wholesaler channel visibility
Why this matters
A supplier list used for vendor due diligence should not treat “labeler” as the same entity as the manufacturing site. In branded oral solids, the labeler is often the brand owner or local subsidiary, while manufacturing can be done by separate Novartis or contracted sites.
Which companies are involved in PROMACTA distribution and wholesale channels?
Answer (structure): Distribution is executed through Novartis’s commercial distribution organization in the US and corresponding logistics partners. Public sources typically do not provide a granular breakdown of logistics providers at the per-bottle level.
What is typically observable
- US wholesaler channel supply is usually controlled by:
- Novartis commercial operations
- established third-party logistics and distribution networks
- For procurement, the practical supplier contact points are:
- Novartis customer service and distribution operations
- contract manufacturing or packaging inquiries only via regulatory/vendor processes
How does the FDA’s manufacturing disclosure affect “supplier” lists for PROMACTA?
Answer (structure): FDA manufacturing disclosures set the regulatory “ground truth” for which sites can manufacture and release PROMACTA tablets. Supplier lists should track:
- drug product sites
- packaging sites
- label control and secondary packaging responsibilities
Operational compliance mapping
For any supply chain or licensing diligence:
- Map each strength and dosage form to its release site
- Confirm whether packaging occurs at the same site or separate facilities
- Ensure there is no mismatch between the supplier on the supply contract and the FDA-listed manufacturing site
How many manufacturing sites supply PROMACTA, and what are common multi-site patterns for oral solids?
Answer (structure): Oral solid products like PROMACTA often have either:
- a primary drug product manufacturing site plus overflow/backup packaging sites, or
- multiple validated manufacturing sites depending on historical tech transfers and scale-up.
Typical multi-site patterns
- API manufactured at one or a small number of qualified sites
- tablet compression/coating at a primary site
- packaging at the same site or split across additional sites for blister/bottle configuration
The supplier count is therefore best extracted from FDA-listed manufacturing and packaging locations tied to the NDA.
Key Takeaways
- Marketing authorization holder in the US: Novartis Pharmaceuticals Corporation.
- “Suppliers” for PROMACTA split into two layers: API (eltrombopag drug substance) and finished-dose tablet manufacturing (drug product), with packaging and distribution layered on top.
- Regulatory-grade supplier lists come from FDA manufacturing disclosures tied to the PROMACTA NDA and its strengths/dosage forms.
- For due diligence or qualification, treat labeler/distributor and manufacturing sites as distinct roles.
FAQs
- Is the PROMACTA labeler the same as the tablet manufacturer?
- How do I find the FDA-listed manufacturing site for PROMACTA tablets by strength?
- How is eltrombopag API sourcing typically represented in FDA records?
- Do PROMACTA tablets have separate packaging and manufacturing sites?
- What’s the best way to convert a PROMACTA “supplier” into an audit-ready vendor for QC/CMC?
References (APA)
- Novartis Pharmaceuticals Corporation. PROMACTA (eltrombopag) prescribing information. FDA label.
- U.S. Food and Drug Administration. Drug product and manufacturing-related labeling records for PROMACTA (eltrombopag).
- U.S. Food and Drug Administration. Orange Book entries for PROMACTA (eltrombopag) under NDA and listed patents/exclusivity (for context on supply timing).
